ALLURION TECHNOLOGIES, INC. (ALUR) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ALLURION TECHNOLOGIES, INC. Do?
ALLURION TECHNOLOGIES, INC. (ALUR) is a micro-cap company in the Healthcare sector, operating within the Medical Equipment industry. The stock has a market capitalization of $10M, making it a notable participant in its sector. Investors researching ALUR stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Medical Equipment space.
ALLURION TECHNOLOGIES, INC. (ALUR) Stock Rating — Avoid (April 2026)
As of April 2026, ALLURION TECHNOLOGIES, INC. receives a Avoid rating with a composite score of 25.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ALUR ranks #4,409 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ALLURION TECHNOLOGIES, INC. ranks #827 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ALUR Stock Price and 52-Week Range
ALLURION TECHNOLOGIES, INC. (ALUR) currently trades at $0.83. The stock gained $0.03 (3.8%) in the most recent trading session. The 52-week high for ALUR is $4.18, which means the stock is currently trading -80.1% from its annual peak. The 52-week low is $0.65, putting the stock 27.3% above its annual trough. Recent trading volume was 126K shares, suggesting relatively thin trading activity.
Is ALUR Overvalued or Undervalued? — Valuation Analysis
ALLURION TECHNOLOGIES, INC. (ALUR) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 0.59x, compared to 1.66x for the average Healthcare stock.
At current multiples, ALLURION TECHNOLOGIES, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
ALLURION TECHNOLOGIES, INC. Profitability — ROE, Margins, and Quality Score
ALLURION TECHNOLOGIES, INC. (ALUR) earns a quality factor score of 34/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -144.8% versus the sector average of -33.1%.
On a margin basis, ALLURION TECHNOLOGIES, INC. reports gross margins of 63.9%, compared to 71.5% for the sector. The operating margin is -232.1% (sector: -66.1%). Net profit margin stands at -189.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -77.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ALUR Debt, Balance Sheet, and Financial Health
Balance sheet data for ALUR is evaluated through our stability factor. The current ratio is 0.33x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $33M. Cash and equivalents stand at $6M.
ALUR has a beta of 1.24, meaning it is more volatile than the broader market — a $10,000 investment in ALUR would be expected to move 24.0% more than the S&P 500 on any given day. The stability factor score for ALLURION TECHNOLOGIES, INC. is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
ALLURION TECHNOLOGIES, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, ALLURION TECHNOLOGIES, INC. reported revenue of $17M and earnings per share (EPS) of $-3.81. Net income for the quarter was $-23M. Gross margin was 63.9%. Operating income came in at $-36M.
In FY 2025, ALLURION TECHNOLOGIES, INC. reported revenue of $15M and earnings per share (EPS) of $-3.81. Net income for the quarter was $-29M. Gross margin was 62.8%. Revenue grew -52.6% year-over-year compared to FY 2024. Operating income came in at $-30M.
In Q3 2025, ALLURION TECHNOLOGIES, INC. reported revenue of $3M and earnings per share (EPS) of $-1.53. Net income for the quarter was $-12M. Gross margin was 49.1%. Revenue grew -50.5% year-over-year compared to Q3 2024. Operating income came in at $-10M.
In Q2 2025, ALLURION TECHNOLOGIES, INC. reported revenue of $3M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-9M. Gross margin was 73.9%. Revenue grew -71.3% year-over-year compared to Q2 2024. Operating income came in at $-7M.
Over the past 8 quarters, ALLURION TECHNOLOGIES, INC. has demonstrated a growth trajectory, with revenue expanding from $12M to $17M. Investors analyzing ALUR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ALUR Dividend Yield and Income Analysis
ALLURION TECHNOLOGIES, INC. (ALUR) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ALUR Momentum and Technical Analysis Profile
ALLURION TECHNOLOGIES, INC. (ALUR) has a momentum factor score of 11/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.
ALUR vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ALLURION TECHNOLOGIES, INC. (ALUR) ranks #827 out of 838 stocks based on the Blank Capital composite score. This places ALUR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ALUR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALUR vs S&P 500 (SPY) comparison to assess how ALLURION TECHNOLOGIES, INC. stacks up against the broader market across all factor dimensions.
ALUR Next Earnings Date
No upcoming earnings date has been announced for ALLURION TECHNOLOGIES, INC. (ALUR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ALUR? — Investment Thesis Summary
The quantitative profile for ALLURION TECHNOLOGIES, INC. suggests caution. The quality score of 34/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 11/100, a headwind for near-term performance. High volatility (stability score 17/100) increases portfolio risk.
In summary, ALLURION TECHNOLOGIES, INC. (ALUR) earns a Avoid rating with a composite score of 25.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALUR stock.
Related Resources for ALUR Investors
Explore more research and tools: ALUR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALUR head-to-head with peers: ALUR vs AZN, ALUR vs SLGL, ALUR vs VMD.